EOLS FY2025 SEC EDGAR DEF 14A #94 of 168 in industry

Evolus, Inc. CEO pay ratio

The CEO earned $6.4M in FY2025 against median worker pay of $181,817 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-29
Industry
Chemicals & Pharmaceuticals
Industry rank
#94/168

Data updated August 2026

Subscribe to Evolus, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
35:1
Below Average (Scale: 0–1000:1)
CEO pay
$6.4M
Median worker
$181,817

Answer first

Evolus, Inc.'s FY2025 CEO total of $6.4M ranks #812 of 1,423 complete filings; its 35:1 pay ratio ranks #1102. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $181,817. Industry placement uses the FY2025 SIC-28 peer cohort (# 94 of 168, 45th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#812
$6.4M of 1,423 FY2025
Ratio rank
#1102
35:1 of 1,423
Industry pct
45th
below the industry median pay ratio

How Evolus, Inc. ranks nationally

Evolus, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$6,412,214 43rd percentile higher than 43% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). This entry sits in this band. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Evolus, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($6.4M) against pay ratio (35:1) for Evolus, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both04601554.09203107.913804661.918406215.933.6:135.8:138:140.2:142.4:1CEO total payPay ratio (CEO : median worker)Evolus, Inc., CEO total pay: 6412214 · Pay ratio (CEO : median worker): 35:1Evolus, Inc.Kiniksa Pharmaceuticals International, plc, CEO total pay: 310707 · Pay ratio (CEO : median worker): 35:1Kiniksa Pharmaceuticals International, plcGeron Corp, CEO total pay: 314826 · Pay ratio (CEO : median worker): 35:1Geron CorpPrecigen, Inc., CEO total pay: 5354329 · Pay ratio (CEO : median worker): 34:1Precigen, Inc.Rhythm Pharmaceuticals, Inc., CEO total pay: 17544525 · Pay ratio (CEO : median worker): 36:1Rhythm Pharmaceuticals, Inc.Cryoport, Inc., CEO total pay: 2392161 · Pay ratio (CEO : median worker): 37:1Cryoport, Inc.
Evolus, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Evolus, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Evolus, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
35:1
FY2025
vs prior FY
+1:1
from FY2024 34:1
CEO $ YoY
-8.4%
$6.4M latest
Filings shown
2
FY2024–2025
Evolus, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $7.0M - $203,184 34:1 -
2025 $6.4M -8.4% $181,817 35:1 +1:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1570562, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
35:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$6.4M
Companies in Industry
168
vs. Industry Median
Below
#94 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Evolus, Inc.: MODEST · HEAVY pay ratio

Evolus, Inc.'s 35:1 ratio ranks #1102 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 35× the median employee ($181,817) in FY2025.

Median employee $181,817 (ELITE-MED); MODEST · HEAVY stamps put about 35 median-wage years per CEO year.

CEO Total Pay

$6.4M

FY2025 Summary Compensation, below median

Pay Ratio

35:1

Below typical

Evolus, Inc. in the lower-ratio third

Evolus, Inc.'s 35:1 ratio ranks #1102 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Evolus, Inc.'s $6.4M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #812 and ratio rank #1102 split - treat 35:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$6.4M
Median Employee Pay
$181,817
Pay Ratio
35:1
Filing Date
2026-04-29

Company Info

Ticker
EOLS
CIK
1570562
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1570562, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Evolus, Inc.'s 35:1 ratio ranks #1102 of 1,423 FY2025 complete filings (lower third by ratio).

Read with Evolus, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Tenable Holdings, Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.4M (Δ $13K lighter vs Evolus, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Myr Group Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.4M (Δ $17K lighter vs Evolus, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
BrightView Holdings, Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.4M (Δ $30K lighter vs Evolus, Inc.); FLOOR · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Old National Bancorp /in/ · HEAVY

ABS(ceo_total_comp) peer at $6.4M (Δ $35K lighter vs Evolus, Inc.); MID · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Kiniksa Pharmaceuticals International, plc (SIC 28 pole)

Kiniksa Pharmaceuticals International, plc stamps MODEST · MICRO nearest in-SIC by ABS(pay_ratio) to Evolus, Inc.'s MODEST filing.
National dual ranks · #812/#1102

Evolus, Inc.'s FY2025 package sits #812 by CEO dollars and #1102 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Evolus, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Evolus, Inc. (CIK 1570562), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.